Additional studies have shown that SP17 is associated with chemotherapy resistance of ovarian clear cell carcinoma, and the inhibition of SP17 can enhance the sensitivity of clear cell carcinoma ES‐2 to paclitaxel.77, 94. The gene discussed is SPA17; the disease is clear cell adenocarcinoma.